English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/111677
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy

AutorParís, Raquel; Morales, Albert ; Coll, Olga; Sánchez-Reyes, Alberto; García-Ruiz, Carmen ; Fernández-Checa, José C.
Fecha de publicación20-dic-2002
EditorAmerican Society for Biochemistry and Molecular Biology
CitaciónJournal of Biological Chemistry 277(51): 49870-49876 (2002)
ResumenGanglioside GD3 (GD3) has emerged as a modulator of cell death pathways due to its ability to interact with mitochondria and disable survival pathways. Because NF-κB activation contributes to cancer therapy resistance, this study was undertaken to test whether GD3 modulates the response of human hepatoblastoma HepG2 cells to radio- and chemotherapy. NF-κB was activated in HepG2 cells shortly after therapeutic doses of ionizing radiation or daunorubicin treatment that translated into up-regulation of κB-dependent genes. These effects were accompanied by minimal killing of HepG2 cells by either ionizing radiation or daunorubicin. However, GD3 pretreatment blocked the nuclear translocation of active κB members, without effect on Akt phosphorylation, induced by either treatment. The suppression of κB-dependent gene induction by GD3 was accompanied by enhanced apoptotic cell death caused by these therapies. Furthermore, the combination of GD3 plus ionizing radiation stimulated the formation of reactive species followed by the mitochondrial release of cytochrome c and Smac/Diablo and caspase 3 activation. Pretreatment with cyclosporin A before radiotherapy protected HepG2 cells from the therapeutic combination of GD3 plus ionizing radiation. These findings underscore a key role of mitochondria in the response of tumor cells to cancer therapy and highlight the potential relevance of GD3 to overcome resistance to cancer therapy by combining its dual action as a mitochondria-interacting and NF-κB-inactivating agent.
Versión del editorhttp://dx.doi.org/10.1074/jbc.M208303200
URIhttp://hdl.handle.net/10261/111677
DOI10.1074/jbc.M208303200
Identificadoresdoi: 10.1074/jbc.M208303200
issn: 0021-9258
Aparece en las colecciones: (IIBB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.